CCO Treatment Updates
New Agents and Treatment Strategies for Treatment-Experienced HIV Patients
New Antiretroviral Agents: Are They Worth the Wait?
|
Module 1 of 4
|
|
|
|
 Topics covered include:
- Introduction
- HIV Nucleoside Analogue Reverse Transcriptase Inhibitors
- HIV Nonnucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs)
- HIV Protease Inhibitors
- HIV Entry Inhibitors
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the current drug development status of selected investigational antiretrovirals Identify new antiretrovirals in existing classes that may provide benefit to treatment-experienced patients List new classes of antiretrovirals with different mechanisms of action from existing classes
|
New Data: Long-Term Studies in Treatment-Experienced Patients
|
Module 2 of 4
|
- Sharon L. Walmsley, MSc, MD, FRCPC
|
|
|
Topics covered include:
- Introduction
- Interpreting Studies of Salvage Regimens
- Recent Data on Boosted-PI Regimens
- Recent Data on Boosted-PI Regimens (Continued)
- Use of a New Class in Treatment-Experienced Patients
Learning Objectives
Upon completion of this activity, participants should be able to:
Describe the results of studies in which a new antiretroviral class was used in salvage regimens Discuss recent data on the use of boosted protease inhibitor regimens in treatment-experienced patients Review important considerations in the interpretation of studies of salvage regimens
|
New Strategies: Optimizing Antiretroviral Therapy for Treatment-Experienced Patients
|
Module 3 of 4
|
|
|
|
Topics covered include:
- Introduction
- Patient-Related Factors
- Patient-Related Factors (Continued)
- Treatment-Related Factors
- Treatment-Related Factors (Continued)
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the importance of establishing a therapeutic partnership with patients to maximize the likelihood of good adherence Review the outcomes of studies of treatment interruptions before initiation of a salvage regimen Describe the role of resistance testing in guiding the selection of effective regimens for treatment-experienced patients
|
New Paradigms in the Management of Treatment-Experienced Patients
|
Module 4 of 4
|
|
|
|
Topics covered include:
- Introduction
- Viral Fitness, Replication Capacity, and Virulence
- Defining Treatment Failure
- Discordant Virologic and Immunologic Responses
- Guidelines for Drug Resistance Testing
Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss appropriate definitions of treatment failure and related concepts including viral fitness and replication capacity Review current understanding of the reasons for discordant immunologic and virologic responses Describe recent insights into reduced susceptibility to enfuvirtide
|
Interactive Case Challenges
Management of a Modestly Treatment-Experienced Patient After Prolonged Treatment Interruption
- William A. O'Brien, MD, MS
|
|
|
 By William A. O'Brien, MD, MS Learning Objectives
Upon completion of this activity, participants should be able to:
Review the strategy of using double-boosted PIs in treatment-experienced patients Discuss the optimal use of enfuvirtide in treatment-experienced patients Describe the impact of resistance mutations on response to subsequent antiretroviral regimens
|
Management of a Multiclass-Experienced HIV-Infected Patient with Virologic Failure
|
|
|
By W. David Hardy, MD Learning Objectives
Upon completion of this activity, participants should be able to:
Discuss the utility of resistance testing in treatment-experienced patients Describe the appropriate management of treatment-related toxicities in the salvage setting Review data on the safety and efficacy of enfuvirtide in treatment-experienced patients
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by University of Alabama School of Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|
|